A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Susceptibility, Antimicrobial, AFB, Rapid Grower, MIC
Test Code19079
CPT Codes
87186
Includes
Amikacin, Cefoxitin, Ciprofloxacin, Clarithromycin, Clofazimine, Doxycycline, Imipenem, Linezolid, Moxifloxacin, Tigecycline, Tobramycin, Trimethoprim/Sulfamethoxazole
Preferred Specimen
Pure culture of a Runyon group IV mycobacteria (Rapid Growers), submitted in appropriate culture media on a plate or slant, safely contained
Minimum Volume
1 slant/plate/broth
Instructions
Identification of the isolate is required.
Isolate safely contained in a double-walled safety container or must be submitted in 95K bag at room temperature. Lowenstein-Jensen or Middlebrook 7H10 agar slant/plate or equivalent or positive AFB broth medium (requires subculture prior to testing) or any solid microbiological medium that supports growth.
Isolate safely contained in a double-walled safety container or must be submitted in 95K bag at room temperature. Lowenstein-Jensen or Middlebrook 7H10 agar slant/plate or equivalent or positive AFB broth medium (requires subculture prior to testing) or any solid microbiological medium that supports growth.
Transport Temperature
Room temperature
Specimen Stability
Room temperature: Determined by viability
Refrigerated: Determined by viability
Frozen: Unacceptable
Refrigerated: Determined by viability
Frozen: Unacceptable
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Mixed cultures or organisms not considered rapid growing mycobacteria • Raw specimens • Frozen isolates • Isolates overgrown with bacteria, yeast, fungi
Methodology
Broth Microdilution
FDA Status
This test was performed using a kit that has not been cleared or approved by the FDA. The analytical performance characteristics of this test have been determined by Quest Diagnostics. This test should not be used for diagnosis without confirmation by other medically established means.
Setup Schedule
Set up: Mon, Tues, Fri a.m.; Report available: 14-21 days
Reference Range
See Laboratory Report
Clinical Significance
The role of rapidly growing Mycobacteria, especially M. fortuitum and M. chelonae, as agents of human disease has become more clearly established in modern times. Primary antitubercular drugs generally are not effective in the treatment of these organisms. Therapy had shifted to the use of antimicrobial agents routinely used to treat other bacterial infections.
Performing Laboratory
Quest Diagnostics Nichols Institute
14225 Newbrook Drive
Chantilly, VA 20153